Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

clude that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCrys
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... NEW YORK , March 27, 2015  Peter ... in Biomedical Science for his pioneering work on how ... the components of a regulatory mechanism that cells use ... proteins. Dr. Walter is a professor of biochemistry at ... the groundwork for treating a range of human diseases ...
(Date:3/27/2015)... 27, 2015 Governor Andrew M. Cuomo ... for 43North - the world’s largest business idea competition ... prize of $1 million, six $500,000 awards and four ... world to compete for prizes that will turn ideas ... Western New York region. , "Last year's successful ...
(Date:3/26/2015)... 26, 2015 The Market Element LLC, ... strategic alliance with Designing Gig LLC to provide website ... , “Forging this alliance with Designing Gig represents ... can extend a comprehensive, end-to-end, digital solution for our ... execution,” said Chuck Miller, president of The Market Element. ...
(Date:3/26/2015)... , March 26, 2015 PAREXEL ... global clinical research organization , announced ... definitive agreement to acquire all of the ... a leading provider of specialized pharmacovigilance services, ... the collection, detection, assessment, monitoring, and prevention ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... a Human Capillary, DUBLIN, Ireland, Jan. ... microfluidic systems in the emerging field of,nano-lifesciences, ... VenaFlux(TM),Platform. The VenaFlux(TM), the first semi-automated, high ... adhesion to,antibody-coated or endothelial- cell cultured microchannels, ...
... Pharmaceuticals Inc.,has announced that its hyaluronic acid therapy, ... sponsor of the EUFLEXXA National,Senior Games Hockey Championships ... "This is such a tremendous opportunity for both ... Product Manager, EUFLEXXA(TM). "We,support all that the National ...
... Workflow and Solutions Division, Siemens Healthcare, to ... Serve as Event ... knowledge are transforming molecular imaging, molecular diagnostics,and informatics to create ... number of critical diseases. These new,diagnostic tools provide physicians with ...
Cached Biology Technology:Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 3Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 4The Dark Report and Siemens Introduce the World's First Integrated Molecular Summit 2The Dark Report and Siemens Introduce the World's First Integrated Molecular Summit 3The Dark Report and Siemens Introduce the World's First Integrated Molecular Summit 4
(Date:3/16/2015)... March 16, 2015 Between ... will present groundbreaking innovations in biometric identification at ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... innovation is well at the forefront: the company,s ... made in Germany . BiometricGate ...
(Date:3/12/2015)... 12, 2015 WHEN:Tuesday, March 17, 2015 at ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan Measurement ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must plan ... several different markets and industries. This is especially ... uptrend. Join Frost & Sullivan,s ...
(Date:3/10/2015)... 2015 Transforming How We Look ... Medicine in Human Space Flight" by Michael ... , Ph.D. was recently featured by Springer Science Media, highlighting ... Specifically, "Personalized Medicine in Human Space Flight" ... in 2013 and 2014 from Springer in the journal ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... seized in tiger range countries over the past decade, according to ... trade monitoring network. Reduced to Skin and Bones shows that from ... tigers were seized in 11 of the 13 tiger range countriesor ... Of the 11, India, China and Nepal ranked highest in the ...
... New Rochelle, NY, November 9, 2010The link between maternal ... (SIDS) may relate to the negative effects of nicotine ... according to an article in the recent issue of ... journal published by Mary Ann Liebert, Inc. ( www.liebertpub.com ...
... - A new study led by scientists at the University ... that over the next century recruitment of new corals could ... oceans more acidic. The research findings reveal a new danger ... "Ocean acidification is widely viewed as an emerging ...
Cached Biology News:More than 1,000 tigers reduced to skin and bones in last decade 2More than 1,000 tigers reduced to skin and bones in last decade 3New report suggests why risk for sudden infant death syndrome is greater in babies of mothers who smoke 2New ocean acidification study shows added danger to already struggling coral reefs 2
... kit contains the basic components required for ... natural and recombinant mouse Dickkopf homolog-1 (Dkk-1) ... kit contains sufficient materials to run ELISAs ... the following conditions are met: The ...
HIV-1 TAT (vN-21)...
Presenilin-1, N-terminus....
Request Info...
Biology Products: